Ipilimumab
Brand: Yervoy (global) / Ipilimumab (IN/BD)
Anticancer
CTLA-4 Immune Checkpoint Inhibitor
Pharmacokinetics
| Half-life | 360 hours |
| Clearance Route | other |
| Active Metabolites | no |
| Notes | RAW70: 3 mg/kg q3wk → ~210 mg x4 doses. Combination with PD-1 increases toxicity, improves efficacy. |
⚠️ Safety & Warnings
Severity: Life-threatening
Adverse Effects:
Severe immune-mediated colitis, hepatitis, dermatitis, endocrine failure
Contraindications:
Severe autoimmune disease
Precautions:
High risk immune toxicity → Early steroids recommended in moderate/severe toxicity